ChemoCentryx Awarded $14 Million NIH Grant to Develop Chemokine-Based Immunomodulators October 13, 2003; San Carlos, Calif. — ChemoCentryx, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded the company
ChemoCentryx and Forest Laboratories to Collaborate on The Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics March 15, 2004; San Carlos, CA and New York, NY — ChemoCentryx, Inc., a privately held focused pharmaceutical company, and Forest
ChemoCentryx Raises $33 Million in Private Financing June 17, 2004; San Carlos, Calif. — ChemoCentryx, Inc. today announced that it has closed a private financing round raising gross proceeds of $33 million. HBM BioVentures and Alta Partners acted as significant new investors in the round.
ChemoCentryx Names Regina E. Herzlinger to the Company's Board of Directors Mountain View, CA; February 7, 2006 — ChemoCentryx, Inc., a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system,